IUPAC/Chemical Name
2-hydroxy-5-(7-hydroxy-8-methyl-6-nitro-2-oxo-2H-chromene-3-carboxamido)benzoic acid
InChi Key
DOLJMUVMVVSXRX-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H12N2O9/c1-7-14(22)12(20(27)28)5-8-4-11(18(26)29-15(7)8)16(23)19-9-2-3-13(21)10(6-9)17(24)25/h2-6,21-22H,1H3,(H,19,23)(H,24,25)
SMILES Code
O=C(O)C1=CC(NC(C2=CC3=CC([N+]([O-])=O)=C(O)C(C)=C3OC2=O)=O)=CC=C1O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
400.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Qi W, Zhao Q, Liu H, Jiang J, Chen X, Hu P. Determination of nicousamide in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013 Apr 15;77:158-62. doi: 10.1016/j.jpba.2013.01.025. Epub 2013 Jan 26. PubMed PMID: 23416370.
2: Zhang S, Li H, Li Y, Zhang F, Liu Y, Chen X. Nicousamide normalizes renovascular hypertension in two-kidney one-clip hypertensive rats. Biomed Rep. 2013 Jan;1(1):89-92. Epub 2012 Oct 22. PubMed PMID: 24648900; PubMed Central PMCID: PMC3956876.
3: Li H, Zhang Y, Wang H, Zheng X, Chen X. Nicousamide blocks the effects of advanced glycation end products on renal cells. Eur J Pharmacol. 2012 Jan 15;674(2-3):455-9. doi: 10.1016/j.ejphar.2011.06.056. Epub 2011 Jul 13. PubMed PMID: 21763303.
4: Sheng L, Hu JP, Chen H, Li Y. [Metabolism of nicousamide in rat and human liver in vitro]. Yao Xue Xue Bao. 2008 Sep;43(9):912-6. Chinese. PubMed PMID: 19048781.
5: Zhang S, Wang D, Xue N, Lai F, Ji M, Jin J, Chen X. Nicousamide protects kidney podocyte by inhibiting the TGFβ receptor II phosphorylation and AGE-RAGE signaling. Am J Transl Res. 2017 Jan 15;9(1):115-125. eCollection 2017 Jan 15. PubMed PMID: 28123638; PubMed Central PMCID: PMC5250708.
6: Sheng L, Chen H, Li Y. A HPLC method for determination of nicousamide in dog plasma and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):99-103. Epub 2007 Apr 13. PubMed PMID: 17452131.
7: Zhang S, Li Y, Li H, Zheng X, Chen X. Renal-protective effect of nicousamide on hypertensive nephropathy in spontaneously hypertensive rats. Biomed Rep. 2013 Jan;1(1):34-40. Epub 2012 Sep 25. PubMed PMID: 24648890; PubMed Central PMCID: PMC3956899.